Xin Du

Dr. Xin Du


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
NANa An
Na An
YHYun Nan Hou
Yun Nan Hou
QZQiao Xia Zhang
Qiao Xia Zhang
TLTing Li
Ting Li
QZQiong Li Zhang
Qiong Li Zhang
XDXin Du
Xin Du

1 November 2018 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
YPYuming Pan
Yuming Pan
JLJin Lou
Jin Lou
HWHeng Wang
Heng Wang
NANa An
Na An
HCHuan Chen
Huan Chen
XDXin Du
Xin Du

1 February 2021 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
YPYuming Pan
Yuming Pan
NANa An
Na An
XDXiaopeng Deng
Xiaopeng Deng
QZQiaoxia Zhang
Qiaoxia Zhang
XDXin Du
Xin Du

15 November 2022 in Blood
Verified
Journal Article
Open access
WCWenming Chen
Wenming Chen
CFChengcheng Fu
Chengcheng Fu
BFBaijun Fang
Baijun Fang
ALAi-Bin Liang
Ai-Bin Liang
ZXZhongjun Xia
Zhongjun Xia
ZLZonghai Li
Zonghai Li
Background: Zevorcabtagene autoleucel (Zevor-cel, CT053), a fully human autologous anti- B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell

15 May 2017 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
YPYan Pang
Yan Pang
HXHaowen Xiao
Haowen Xiao
HZHang Zhang
Hang Zhang
ZLZeng-Hui Liu
Zeng-Hui Liu
LLLi Li
Li Li
YXYang Xiao
Yang Xiao
We conducted a phase II, noncomparative, multicenter study to assess the efficacy and safety of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) expanded in vitro for patients with aplastic anemia (AA) refractory to immunosuppressive therapy. Seventy-four patients from seven centers received allogeneic BM-MSCs at a dose of 1–2 × 106 cells/kg per week for 4 weeks. Responses were assessed at 0.5, 1, 2, 3, 6, 9, and 12 months after the first cells infusion. Patients with response at 1 month continued to receive four infusions. All patients were evaluable. The overall response rate was 28.4% (95% confidence interval, 19%–40%), with 6.8% complete response and 21.6% partial response. The median times to response of leukocytic, erythrocytic, and megakaryocytic linages were 19 (range, 11–29), 17 (range, 12–25), and 31 (range, 26–84) days, respectively. After median follow-up of 17 months, overall survival was 87.8%. Seven patients developed transitory and mild headache and fever, but no other adverse events were observed. Antithymocyte globulin used in previous treatment and no activated infection throughout treatment were predictors for response. Allogeneic BM-MSCs infusion is a feasible and effective treatment option for refractory AA. The trial was registered at www.clinicaltrials.gov as NCT00195624.

24 December 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LYLinlin Yang
Linlin Yang
BZBarbara Zerbato
Barbara Zerbato
APAlex Pessina
Alex Pessina
LBLuca Brambilla
Luca Brambilla
VAVirginia Andreani
Virginia Andreani
BGBodo Grimbacher
Bodo Grimbacher
Background: Hypomorphic mutations in the phosphoacetylglucosamine mutase 3 (PGM3) gene cause a glycosylation disorder that leads to immunodeficiency. It is often associated with recurrent infections and atopy. The exact etiology of this condition remains unclear.Objective: This study aimed to characterize the phenotypes and immunological features associated with PGM3 insufficiency and investigate potential disease mechanisms.Methods: A systematic review of 44 published cases of PGM3 variants was performed, followed by T-cell phenotyping of two patients with PGM3 variants. A genotype-phenotypic severity study was conducted by comparing the residual PGM3 expression of the 12 reconstituted variants in human B cells. A PGM3 inhibitor was used to assess its effect on CD4+ T cell proliferation and differentiation.Results: Patients with PGM3 variants frequently presented with recurrent infections and atopy, accompanied by reduced naïve CD4+ T cell counts. A genotype–phenotype study showed that low levels of residual PGM3 expression are correlated with disease severity. Notably, inhibition of PGM3 activity impaired TCR-mediated CD4+ T cell proliferation and the synthesis of UDP-GlcNAc, complex N-glycans, O-GlcNAc, glycolytic stress, and mitochondrial respiration during proliferation in a dose-dependent manner. Partial loss of PGM3 activity was observed to preferentially enhance Th1 and Th2 differentiation, while attenuating Th17 and Treg differentiation, consistent with clinical observations.Conclusion: PGM3 is a critical regulator of CD4+ T-cell proliferation and differentiation. These findings provide new insights into the diverse clinical manifestations and therapeutic development of PGM3 deficiency.